JP2013510875A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510875A5
JP2013510875A5 JP2012539026A JP2012539026A JP2013510875A5 JP 2013510875 A5 JP2013510875 A5 JP 2013510875A5 JP 2012539026 A JP2012539026 A JP 2012539026A JP 2012539026 A JP2012539026 A JP 2012539026A JP 2013510875 A5 JP2013510875 A5 JP 2013510875A5
Authority
JP
Japan
Prior art keywords
dapagliflozin
propylene glycol
magnesium stearate
starch glycolate
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539026A
Other languages
English (en)
Japanese (ja)
Other versions
JP5784623B2 (ja
JP2013510875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056577 external-priority patent/WO2011060290A2/en
Publication of JP2013510875A publication Critical patent/JP2013510875A/ja
Publication of JP2013510875A5 publication Critical patent/JP2013510875A5/ja
Application granted granted Critical
Publication of JP5784623B2 publication Critical patent/JP5784623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539026A 2009-11-13 2010-11-12 速放性錠剤製剤 Expired - Fee Related JP5784623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26117309P 2009-11-13 2009-11-13
US61/261,173 2009-11-13
PCT/US2010/056577 WO2011060290A2 (en) 2009-11-13 2010-11-12 Immediate release tablet formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015019631A Division JP2015129142A (ja) 2009-11-13 2015-02-03 速放性錠剤製剤

Publications (3)

Publication Number Publication Date
JP2013510875A JP2013510875A (ja) 2013-03-28
JP2013510875A5 true JP2013510875A5 (cg-RX-API-DMAC7.html) 2013-12-26
JP5784623B2 JP5784623B2 (ja) 2015-09-24

Family

ID=43413349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012539026A Expired - Fee Related JP5784623B2 (ja) 2009-11-13 2010-11-12 速放性錠剤製剤
JP2015019631A Pending JP2015129142A (ja) 2009-11-13 2015-02-03 速放性錠剤製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015019631A Pending JP2015129142A (ja) 2009-11-13 2015-02-03 速放性錠剤製剤

Country Status (21)

Country Link
US (1) US8871264B2 (cg-RX-API-DMAC7.html)
EP (1) EP2498759B1 (cg-RX-API-DMAC7.html)
JP (2) JP5784623B2 (cg-RX-API-DMAC7.html)
CN (2) CN104825417A (cg-RX-API-DMAC7.html)
AU (1) AU2010319377B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011733A2 (cg-RX-API-DMAC7.html)
CA (2) CA3002948C (cg-RX-API-DMAC7.html)
CY (1) CY1121107T1 (cg-RX-API-DMAC7.html)
DK (1) DK2498759T3 (cg-RX-API-DMAC7.html)
ES (1) ES2693686T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181755T1 (cg-RX-API-DMAC7.html)
LT (1) LT2498759T (cg-RX-API-DMAC7.html)
MX (1) MX2012005365A (cg-RX-API-DMAC7.html)
PL (1) PL2498759T3 (cg-RX-API-DMAC7.html)
PT (1) PT2498759T (cg-RX-API-DMAC7.html)
RS (1) RS57926B1 (cg-RX-API-DMAC7.html)
RU (2) RU2558798C2 (cg-RX-API-DMAC7.html)
SI (1) SI2498759T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800564T1 (cg-RX-API-DMAC7.html)
TR (1) TR201816242T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011060290A2 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt­2 억제제
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
ES2596202T3 (es) 2009-09-30 2017-01-05 Boehringer Ingelheim International Gmbh Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
CN102711739B (zh) * 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP2529742B1 (en) * 2011-06-03 2013-11-20 ratiopharm GmbH Pharmaceutical composition comprising dapagliflozin and cyclodextrin
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
AU2012362562B2 (en) * 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
TR201202948A2 (tr) 2012-03-15 2012-07-23 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Dapagliflozin ve uzatılmış salınımlı metaformin içeren tablet formülasyonu.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
JP6574417B2 (ja) * 2013-07-22 2019-09-11 サンド・アクチエンゲゼルシヤフト 非晶質ダパグリフロジンを含有する製剤
CN103463090A (zh) * 2013-09-11 2013-12-25 深圳翰宇药业股份有限公司 西他列汀盐酸二甲双胍复方制剂的制备方法
US20170056365A1 (en) * 2014-02-28 2017-03-02 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
CN103976997B (zh) * 2014-05-13 2016-08-17 中国药科大学 一种降血糖复方缓释胶囊及其制备方法
CN106924208A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法
US10489509B2 (en) * 2016-03-14 2019-11-26 International Business Machines Corporation Personality based sentiment analysis of textual information written in natural language
CN106176718A (zh) * 2016-08-03 2016-12-07 上海延安药业有限公司 复方卡格列净二甲双胍片
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
CN106924237B (zh) * 2017-03-03 2019-12-03 杭州华东医药集团新药研究院有限公司 一种含有恩格列净和盐酸二甲双胍的药物组合物
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
WO2018200534A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
AU2018258170B2 (en) * 2017-04-25 2023-06-29 Otsuka Pharmaceutical Co., Ltd. Lisinopril compositions with an ingestible event marker
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
KR102369679B1 (ko) * 2017-09-29 2022-03-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
MX2020008546A (es) * 2018-02-21 2021-01-08 Glenmark Pharmaceuticals Ltd Composicion farmaceutica que comprende remogliflozina y un agente antidiabetico.
BR112020024269A2 (pt) * 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
WO2020089761A1 (en) * 2018-11-01 2020-05-07 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
TR202004809A2 (tr) * 2020-03-27 2021-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve dapagli̇flozi̇n i̇çeren bi̇r saşe formülasyonu
CN115867538A (zh) 2020-06-05 2023-03-28 新梅斯托克公司 高纯的无定形达格列净的制备
CN111956622B (zh) * 2020-09-15 2022-11-15 北京福元医药股份有限公司 一种达格列净丙二醇水合物药物制剂
CN112206216B (zh) * 2020-10-15 2023-03-17 江西华士药业有限公司 一种缓释达格列净的制备方法
US20220160619A1 (en) * 2020-11-25 2022-05-26 Complete Medical Solutions, Llc Effervescent Drug Formulations
TR202019590A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
WO2022119543A1 (en) 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR202019589A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
EP4079296A1 (en) 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
EP4212150A1 (en) 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物
KR20240107660A (ko) * 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
EP4431088A1 (en) 2023-03-06 2024-09-18 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
EP4427742A1 (en) 2023-03-06 2024-09-11 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
CN122438678A (zh) 2023-12-22 2026-07-21 新梅斯托克公司 包含达格列净和二甲双胍的双层片剂制剂

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (cg-RX-API-DMAC7.html) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
HU198005B (en) 1984-12-04 1989-07-28 Sandoz Ag Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DK277488A (da) 1987-05-22 1988-11-23 Squibb & Sons Inc Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
EP1062222A1 (en) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP4848558B2 (ja) 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
GEP20063908B (en) 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
EP1841414A1 (en) 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
WO2007078726A2 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
WO2007131930A1 (en) 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR100812538B1 (ko) 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
CL2007003227A1 (es) 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
EP2139464A1 (en) 2007-03-15 2010-01-06 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
EP2011808A1 (de) 2007-07-03 2009-01-07 Bayer MaterialScience AG Medizinische Klebstoffe für die Chirurgie
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
EP2249643A4 (en) 2008-02-05 2013-10-09 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE IV HEMMER
AU2009220444A1 (en) 2008-03-04 2009-09-11 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009143021A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
CN102711739B (zh) * 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂

Similar Documents

Publication Publication Date Title
RU2015122253A (ru) Составы таблетки с немедленным высвобождением
JP4969586B2 (ja) マルチプルユニット型徐放性経口製剤およびその製造方法
JP2013510873A5 (cg-RX-API-DMAC7.html)
US7585520B2 (en) Compositions containing both sedative and non-sedative antihistamines and sleep aids
TWI327471B (en) Pharmaceutical formulations of 5,8,14-triazatetracyclo[10.3.1.02,11.o4,9]-hexadeca-2(11),3,5,7,9-pentaene
JP6976946B2 (ja) 生理活性の強い、urat1のインヒビターを含む医薬組成物
US20080026059A1 (en) Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline
US20090137684A1 (en) Sustained-release preparations and method for producing the same
TW200408394A (en) Matrix for sustained, invariant and independent release of active compounds
AU2020294268A1 (en) Sustained-release formulations of colchicine and methods of using same
KR20140053307A (ko) 맛이 차폐된 약제학적 조성물
CN102316857A (zh) 防止误用的控释配方
WO2010138439A1 (en) Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
EP2496217B1 (en) Direct compression tablets of otilonium
EP2606879A1 (en) Multiple unit pellet tablet formulation comprising an opioid
KR20090119986A (ko) 시간 특이적 지연성/맥동성 방출 투약 형태
TWI823471B (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
TW201309349A (zh) 醫藥調配物
JP2013538807A (ja) メトホルミンおよびピオグリタゾンを含む医薬組成物
CN102727456A (zh) 难溶性药物口腔崩解片及其制备方法
WO2018206923A1 (en) Novel formulations
WO2014096982A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
EP3697392A1 (en) Tablets comprising tamsulosin and solifenacin
CN108721239A (zh) 一种治疗阿尔茨海默病的缓释制剂及其制备方法
CN104000821B (zh) 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法